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Abstract
Mismatch between CSF and PET amyloid-β biomarkers occurs in up to ≈20% of preclinical/prodromal Alzheimer’s disease
individuals. Factors underlying mismatching results remain unclear. In this study we hypothesized that CSF/PET
discordance provides unique biological/clinical information. To test this hypothesis, we investigated non-demented and
demented participants with CSF amyloid-β42 and [18F]Florbetapir PET assessments at baseline (n= 867) and at 2-year
follow-up (n= 289). Longitudinal trajectories of amyloid-β positivity were tracked simultaneously for CSF and PET
biomarkers. In the longitudinal cohort (n= 289), we found that participants with normal CSF/PET amyloid-β biomarkers
progressed more frequently toward CSF/PET discordance than to full CSF/PET positivity (χ2(1)= 5.40; p < 0.05).
Progression to CSF+/PET+ status was ten times more frequent in cases with discordant biomarkers, as compared to
csf−/pet− cases (χ2(1)= 18.86; p < 0.001). Compared to the CSF+/pet− group, the csf−/PET+ group had lower APOE-
ε4ε4 prevalence (χ2(6)= 197; p < 0.001; n= 867) and slower rate of brain amyloid-β accumulation (F(3,600)= 12.76; p <
0.001; n= 608). These results demonstrate that biomarker discordance is a typical stage in the natural history of amyloid-β
accumulation, with CSF or PET becoming abnormal first and not concurrently. Therefore, biomarker discordance allows for
identification of individuals with elevated risk of progression toward fully abnormal amyloid-β biomarkers, with subsequent
risk of neurodegeneration and cognitive decline. Our results also suggest that there are two alternative pathways (“CSF-first”
vs. “PET-first”) toward established amyloid-β pathology, characterized by different genetic profiles and rates of amyloid-β
accumulation. In conclusion, CSF and PET amyloid-β biomarkers provide distinct information, with potential implications
for their use as biomarkers in clinical trials.
Introduction
The abnormal deposition of amyloid-β into plaques is con-
sidered one of the earliest neuropathological events in Alz-
heimer’s disease. Current research diagnostic criteria for
Alzheimer’s disease promote the use of either CSF (low levels
of CSF amyloid-β42) or PET imaging (high brain retention of
amyloid-β PET tracers) as equivalent measures of amyloid-β
pathology [1–4]. Amyloid-β PET and CSF amyloid-β42
usually provide highly concordant information, which has
justified their interchangeable use in the diagnosis of Alz-
heimer’s disease dementia [5, 6]. However, a significant
proportion of cases showing discordant CSF and PET results
has been consistently reported across multiple studies [6–34]
(Supplementary Table 1), reaching up to ≈20% in prevalence
[15] in preclinical/prodromal disease phases (e.g.,
[13–15, 18, 19, 28]). To date, the interpretation of the CSF/
PET discordant findings is still unclear and the longitudinal
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evolution of the concordant and discordant CSF/PET groups
remains unknown. While it has been suggested that dis-
cordance in amyloid-β biomarkers might be related to mea-
surement issues, due to different detection thresholds of CSF
vs. PET techniques [13], recent studies have indicated that
biomarker discordance might be biologically relevant, with
each amyloid-β biomarker providing distinct information
[15, 19, 35]. There are several reasons to hypothesize that
CSF and PET biomarkers measure different aspects of
amyloid-β pathology. CSF amyloid-β42 is a marker of soluble
amyloid-β, only indirectly related to fibrillar amyloid-β in the
brain [36]. Furthermore, CSF amyloid-β42 can be affected by
variations in amyloid precursor protein and amyloid-β pro-
duction, and by non-fibrillar aggregation [12]. On the other
hand, amyloid-β PET is a direct measure of fibrillar amyloid-β
deposition in the brain, as reported in antemortem-
postmortem correlative studies [37–40].
Hence, we hypothesize that discordance in amyloid-β
biomarkers provides unique information and that the exis-
tence of discordant groups may result from differences in
amyloid-β processing and kinetics in the CSF vs. in the brain.
In particular, while CSF amyloid-β42 represents an instanta-
neous measure of ongoing amyloid-β accumulation, reflecting
the availability of soluble amyloid-β in the CSF, amyloid-β
PET represents an integral measure of previously accumu-
lated amyloid-β, providing information on the resulting
fibrillar amyloid-β plaque accumulation. Thus, we expect the
instantaneous CSF amyloid-β42 concentration to be predictive
of the subsequent rate of change in amyloid-β PET standar-
dized uptake value ratio (SUVr), but not vice-versa. To test
this hypothesis, we aimed to: (a) test whether baseline CSF
amyloid-β42 levels significantly predict future rate of change
in amyloid-β PET SUVr; (b) test whether amyloid-β PET
SUVr at baseline does not significantly predict rate of change
of CSF amyloid-β42; (c) investigate the longitudinal evolution
of CSF amyloid-β42 and amyloid-β PET biomarkers in a
longitudinal cohort of participants stratified into four
groups of concordant and discordant biomarkers (csf−/pet−,
CSF+/pet−, csf−/PET+, and CSF+/PET+).
Participants and methods
Study design
Data used in the preparation of this article were obtained from
the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
database (adni.loni.usc.edu). The ADNI was launched in 2003
as a public–private partnership, led by Principal Investigator
Michael W. Weiner, MD. The primary goal of ADNI has
been to test whether serial MRI, PET, other biological mar-
kers, and clinical and neuropsychological assessment can be
combined to measure the progression of mild cognitive
impairment and early Alzheimer’s disease. In the current
study, we included all ADNI participants with available
concurrent CSF amyloid-β42 and [18F]Florbetapir PET ima-
ging measurements, obtained within a 3-month time interval.
All participants gave written informed consent, as approved
by local ethics committees and in accordance with the
Declaration of Helsinki. For up-to-date information, see
www.adni-info.org.
Participants
Data were downloaded from the ADNI database on October
24, 2018. Our cohort consisted of n= 867 demented
patients and non-demented participants, with available CSF
amyloid-β42 and [18F]Florbetapir PET imaging at baseline,
obtained between April 2010 and April 2014 at 57
ADNI sites, within a time interval between CSF and PET
measurements of 90 days (Δt= 0.08 ± 17.18 days). A
total of n= 608 cases had a second [18F]Florbetapir PET
scan performed after approximately 2 years (Δt= 2.01 ±
0.68 years) and n= 348 cases had a third scan after 4 years
(Δt= 4.28 ± 0.63 years) from the baseline scan. A total of
n= 305 had a second CSF amyloid-β42 measurement after
~2 years from baseline (Δt= 2 ± 0.11 years).
CSF amyloid-β42
Following overnight fasting, CSF samples were acquired in
the morning through lumbar puncture. CSF amyloid-β42
measurement was performed based on the multiple xMAP
Luminex platform (Luminex Corp) with INNO-BIA Alz-
Bio3 immunoassay kit (Innogenetics) [41]. Longitudinal
CSF samples belonging to the same participant were mea-
sured on the same plate. All data were derived from the
UPENNBIOMK_MASTER.csv dataset.
Amyloid-β PET
[18F]Florbetapir PET acquisition and analysis are thor-
oughly described elsewhere [13]. Following recommenda-
tions for longitudinal studies [42] we selected a composite
reference region, including the whole cerebellum, brain-
stem/pons, and subcortical white matter, for SUVr estima-
tion. A summary measure of global cortical uptake was
calculated as the weighted-average uptake across regions of
interest including frontal, anterior/posterior cingulate, lateral
parietal, and lateral temporal lobes. All data were derived
from the UCBERKELEYAV45_08_09_18.csv dataset.
Other data
Additional baseline and longitudinal measures of neurode-
generation, tau pathology, cognition, and neuropsychiatric
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symptomatology were available; genetic information was
also retrieved. Number of participants with additional data
available, at baseline and at follow-ups, is reported in the
next paragraphs.
FDG-PET
FDG-PET acquisition and analysis are thoroughly described
elsewhere [43]. A composite index for Alzheimer’s disease-
like hypometabolism was available in n= 857 participants
(n= 417 at 2-year follow-up). Data were retrieved from the
ADNIMERGE.csv dataset.
Structural MRI
T1-weighted MRI image acquisition and analysis are thor-
oughly described elsewhere [44]. Hippocampal, ventricles
and whole-brain volume data were available in n= 799
participants (n= 614 at 1-year, n= 427 at 1.5-year, n= 335
at 2-year follow-up). Volumes of target regions were cor-
rected for total intracranial volume. Data were retrieved
from ADNIMERGE.csv dataset.
Other MRI measures
Presence, localization and size of infarcts were evaluated by
trained physicians on T1- and T2-weighted and FLAIR
MRI images in n= 818 participants [45]. Volume of white
matter hyperintensities, indexing vascular brain injury, was
quantified based on a Bayesian approach to segment high-
resolution T1 and FLAIR MRI images in n= 816 partici-




CSF phosphorylated-tau181 (n= 867 at baseline; n= 307 at
2-year follow-up) and total-tau (n= 866 at baseline; n=
306 at 2-year follow-up) measurements were derived
through AlzBio3 immunoassay. Data were retrieved from
the UPENNBIOMK_MASTER.csv dataset. CSF amyloid-
β40 measurements were obtained in n= 822 participants at
baseline through 2D-UPLC-tandem mass spectrometry.
Data were retrieved from the UPENNMSMSABETA.csv
and UPENNMSMSABETA2.csv datasets.
Cognitive and neuropsychiatric measures
We took into account the following scales for cognitive
evaluation: Mini-Mental State Examination (MMSE)
(available in n= 867 participants, plus n= 711 at ~1-year,
n= 665 at 2-year, n= 535 at 3.5-year follow-up);
Alzheimer’s disease Assessment Scale-cognitive subscale
(ADAS-cog11) (n= 867; 724; 657; 528); Rey Auditory
Verbal Learning Test (RAVLT), learning subscale (n=
866; 722; 657; 520).
Severity of depression and sleep disorders were eval-
uated by means of the Geriatric Depression Scale (GDS)
(n= 865) and Neuropsychiatric Inventory, sleep subscale
(NPI-K) (n= 860), respectively. Data were retrieved from
the ADNIMERGE.csv, GDSSCALE.csv, and NPI.csv
datasets.
Genetic data
APOE genotyping was performed using DNA extracted by
Cogenics from a 3 ml aliquot of whole blood (n= 867). We
considered both the number of APOE-ε4 and APOE-ε2
alleles. Polygenic hazard score (n= 783) was computed
based on a combination of APOE and 31 other genetic
variants, as detailed elsewhere [47]. Data were retrieved
from the APOE.csv and DESIKANLAB.csv datasets.
Statistical analysis
Multivariable regression analyses
We fitted linear, quadratic, and cubic regression models,
testing whether baseline CSF amyloid-β42 predicted the rate
of change in [18F]Florbetapir PET SUVr (over 2-year and
4-year follow-up; n= 608 and n= 348 participants,
respectively), and whether baseline [18F]Florbetapir PET
SUVr predicted the rate of change in CSF amyloid-β42 (over
2-year follow-up; n= 305 participants). CSF amyloid-β42
and [18F]Florbetapir PET were included in the regression
models as continuous variables. Sex, age, number of APOE-
ε4 alleles and clinical group were entered as nuisance
covariates. The assumptions of normal distribution and
homoscedasticity of residuals, as well as the absence of
multicollinearity between predictors, were tested and met in
all regression models.
Classification of participants
Participants were classified as either csf−/pet−,
csf−/PET+, CSF+/pet− or CSF+/PET+, based on cutoffs
for abnormality of CSF amyloid-β42 and [18F]Florbetapir
PET biomarkers. CSF amyloid-β42 measurements were
classified as abnormal (CSF+) when <192 pg/ml. This
cutoff was initially established to allow optimal dis-
crimination between healthy controls and Alzheimer’s dis-
ease cases confirmed at autopsy [48] and later validated
using a diagnosis-free data-driven approach [49]. [18F]
Florbetapir PET images were classified as abnormal (PET
+) when global cortical uptake was >0.79 SUVr [42].
Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β. . .
This cutoff (optimized for longitudinal studies) was derived
using linear regression from a well-validated cutoff for
cross-sectional assessment (1.11 SUVr) [42], initially
derived in healthy controls [50], then validated for dis-
crimination between autopsy-confirmed healthy controls
and Alzheimer’s disease patients [51], and again using
mixture model analysis [35].
Longitudinal analyses
To investigate the simultaneous longitudinal changes in
CSF amyloid-β42 and [18F]Florbetapir PET biomarkers,
stratified by csf−/pet−, csf−/PET+, CSF+/pet− or
CSF+/PET+ subgroups, we selected all participants (n=
289) with CSF and PET amyloid-β biomarkers available
both at baseline and at the 2-year follow-up examinations,
and obtained within 90 days. Differences in prevalence of
longitudinal outcomes across subgroups were tested by
means of χ2 tests.
Group comparisons
Group comparisons for continuous variables were per-
formed via general linear modeling. Post-hoc tests were
performed using Bonferroni correction for multiple
comparisons. The assumptions of normality of residuals
and homoscedasticity were tested; when not met, the
estimates were bootstrapped with 1000 replicates, gen-
erating bias-corrected and accelerated 95% confidence
intervals. For categorical variables, χ2 tests were applied.
Cox regression analysis was used for estimation of hazard
risks. When the assumption of proportionality of hazards
was not met, we run a stratified model. Sex, age, number
of APOE-ε4 alleles, and clinical group were included as
nuisance covariates.
All statistical analyses were performed in PASW Sta-
tistics 18 (SPSS Inc.), setting the significance level at p <
0.05 (two tailed). Graphical renderings were performed in
RStudio (v.1.1.456, http://www.rstudio.com/), using
ggplot2 v.2.2.1.
Results
Longitudinal changes in amyloid-β CSF and PET
measures in the whole cohort
Table 1 shows baseline demographic and clinical char-
acteristics of the participants, divided by clinical group
(n = 867).
Table 1 Baseline descriptive statistics of the study cohort.
Healthy controls Subjective memory
complaints




N (%) 185 (21.34) 90 (10.38) 445 (51.33) 147 (16.96) –




247/198 (55.51/44.49) 88/59 (59.86/40.14) χ2(3)= 11.79;
p < 0.01



































































Results from GLM are corrected for sex, age, and number of APOE-ε4 alleles. Data are reported as mean ± standard deviation, unless indicated
otherwise. Adjusted estimates of the mean and the respective standard error are reported in square brackets. Sex, age, number of APOE-ε4 alleles,
and clinical group were entered as nuisance covariates. For groups where variables are non-normally distributed, median (interquartile range) is
also reported, in italics.
MMSE Mini-Mental State Examination, SUVr standardized uptake value ratio.
1Results of post-hoc comparisons, Bonferroni-corrected for multiple comparisons; significant differences:
aHealthy controls vs. mild cognitive impairment; subjective cognitive complaints vs. Alzheimer’s disease dementia; mild cognitive impairment vs.
Alzheimer’s disease dementia.
bHealthy controls vs. mild cognitive impairment; healthy controls vs. Alzheimer’s disease dementia; subjective cognitive complaints vs. mild
cognitive impairment; subjective cognitive complaints vs. Alzheimer’s disease dementia; mild cognitive impairment vs. Alzheimer’s disease
dementia.
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Testing of our hypothesis by means of standard regres-
sion models in the whole cohort, considering participants
with longitudinal amyloid-β CSF (n= 305) and PET (n=
608; n= 348) measurements, confirmed both our predic-
tions, i.e.,: (i) baseline CSF amyloid-β42 values significantly
predicted the rate of change in [18F]Florbetapir PET SUVr,
as computed over a 2-year (F(5,602)= 12.11, p < 0.001; n=
608; Fig. 1) and 4-year (F(5,342)= 15.11, p < 0.001; n= 348;
data not shown) time interval. Thus, CSF amyloid-β42 levels
linearly predicted [18F]Florbetapir PET accumulation, with
lower CSF amyloid-β42 levels associated with faster brain
[18F]Florbetapir PET accumulation. Quadratic and cubic
terms did not reach statistical significance in the respective
models. (ii) Neither linear, quadratic nor cubic regression
models significantly predicted the 2-year rate of change in
CSF amyloid-β42 values as a function of baseline [18F]
Florbetapir PET SUVr (F(4,302)= 1.06, p= 0.374;
F(5,301)= 0.92, p= 0.471; F(6,300)= 0.95, p= 0.462,
respectively; n= 305; Fig. 1).
Longitudinal changes in amyloid-β CSF and PET
measures for each of the CSF/PET subgroups
Table 2 shows baseline demographic and clinical char-
acteristics of the participants, divided by CSF amyloid-β42
and [18F]Florbetapir PET biomarker profiles (n= 867).
The assessment of simultaneous 2-year longitudinal
changes in both CSF amyloid-β42 and [18F]Florbetapir PET
biomarkers in participants with both amyloid-β CSF and
PET measurements available, obtained within 90 days, both
at baseline and at 2-year follow-up (n= 289; Fig. 2),
showed that participants with normal CSF amyloid-β42 and
[18F]Florbetapir PET biomarkers (csf−/pet− group) were
more likely to progress to isolated CSF amyloid-β42 posi-
tivity or to isolated [18F]Florbetapir PET positivity
than to progress directly to full biomarker positivity (10.5%
[n= 12/115] vs. 2.6% [3/115] of baseline csf−/pet− cases,
χ2(1)= 5.40; p < 0.05). The frequency of progression to
full biomarker positivity was significantly higher in both
CSF+/pet− and csf−/PET+ groups (25.8% [n= 8/31]),
compared to the csf−/pet− group (2.6% [n= 3/115])
(χ2(1)= 18.69; p < 0.001; χ2(1)= 9.97; p < 0.005, respec-
tively), with no significant differences between CSF+/pet−
and csf−/PET+ groups (χ2(1)= 0.26; p= 0.613). Finally,
CSF+/PET+ participants were highly stable, with full
biomarker positivity representing the endpoint of amyloid-β
biomarkers changes for 99.3% [n= 142/143] of all cases.
At baseline (n= 867), when compared to the remaining
groups, the groups with discordant amyloid-β biomarkers
presented with “intermediate” levels of the pathological
amyloid-β biomarker, i.e., (i) the CSF+/pet− group had
significantly lower CSF amyloid-β42 levels than those with
normal CSF amyloid-β42 values (both csf−/pet− and
csf−/PET+), but significantly higher CSF amyloid-β42
levels as compared to the CSF+/PET+ group; (ii) the
csf−/PET+ group had significantly higher [18F]Florbetapir
Fig. 1 Hypothesis validation—continuous measures. Scatter plots
show the association between baseline CSF amyloid-β42 vs. long-
itudinal changes in [18F]Florbetapir PET SUVr (left panel) and vice-
versa (right panel). Baseline CSF amyloid-β42 significantly predicts the
rate of change in [18F]Florbetapir PET SUVr, as computed on a 2-year
time interval (left panel), the association being represented by a linear
regression model. [18F]Florbetapir PET SUVr does not predict the rate
of change in CSF amyloid-β42, as computed on a 2-year time interval
(right panel). Aβ42 amyloid-β42, ADD Alzheimer’s disease dementia,
HC healthy control, MCI mild cognitive impairment, SMC subjective
memory complaints, SUVr standardized uptake value ratio.
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PET retention compared to either the csf−/pet− or
CSF+/pet− groups but significantly lower as compared to
the CSF+/PET+ level (Table 2). This pattern was con-
sistently observed at the regional level as well (Supple-
mentary Fig. 1; Supplementary Table 2). We also observed
a dissociation between baseline [18F]Florbetapir PET
retention and the rate of [18F]Florbetapir PET accumula-
tion, where rates of [18F]Florbetapir PET accumulation
are expressed in ΔSUVr/year, as computed over 2-year
(n= 608) and 4-year (n= 348) follow-up time intervals.
Significant [18F]Florbetapir PET accumulation rates were
reported in CSF+/PET+ [95% CI at 2 y: 0.009–0.012; 4 y:
0.011–0.013] and CSF+/pet− cases [95% CI at 2 y:
0.003–0.009; 4 y: 0.004–0.009], while minimal to null
accumulation was present in csf−/pet− [95% CI at 2 y:
0.001–0.002; 4 y: 0–0.002] and csf−/PET+ [95% CI at 2 y:
0–0.003; 4 y: 0–0.005] cases (Supplementary Fig. 1; Sup-
plementary Table 2).
When systematically comparing discordant and con-
cordant groups considering (i) biomarkers for tau pathology
and neurodegeneration, (ii) clinical and neuropsychological
measures, (iii) genetic assessments and (iv) confounding
factors (data available in up to n= 867 participants; see
“Participants and Methods” for the precise values), we
found that:
(i) A systematic comparison of biomarkers for tau
pathology and neurodegeneration among CSF/PET groups
revealed no significant differences between the CSF+/pet−
and csf−/PET+ groups. Only the CSF+/PET+ group
presented with increased baseline tau pathology (as mea-
sured by CSF phosphorylated-tau181) and neurodegenera-
tion (as measured by CSF total-tau, [18F]
Fluorodeoxyglucose PET, and MRI), and faster rate of
neurodegeneration as compared to the csf−/pet− group
(Supplementary Table 3).
(ii) Groups with discordant biomarkers were not at
increased risk of clinical progression (csf−/PET+: hazard
risk = 1.14 [95% CI: 0.44–2.99], p= 0.789; CSF+/pet−:
hazard risk= 1.59 [95% CI: 0.74–3.42], p= 0.235) as
compared to the csf−/pet− group, and in contrast with the
CSF+/PET+ group (hazard risk= 4.12 [95% CI:
2.59–6.56], p < 0.001). Discordant groups presented no
difference in either baseline levels or rate of cognitive
decline as measured by MMSE, ADAS-cog11 and
Table 2 Baseline descriptive statistics for concordant and discordant biomarker groups.
csf−/pet− csf−/PET+ CSF+/pet− CSF+/PET+ Test value; p
value1
N (%) 300 (34.60) 44 (5.07) 62 (7.15) 461 (53.17) –
































































































Results from GLM are corrected for sex, age, diagnostic group and number of APOE-ε4 alleles. Data are reported as mean ± standard deviation,
unless indicated otherwise. Adjusted estimates of the mean and the respective standard error are reported in square brackets. Sex, age, number of
APOE-ε4 alleles and clinical group were entered as nuisance covariates. For groups where variables are non-normally distributed, median
(interquartile range) is also reported, in italics.
MMSE Mini-Mental State Examination, SUVr standardized uptake value ratio.
1Significant differences after post-hoc comparisons, at p < 0.05, Bonferroni-corrected for multiple comparisons:
acsf−/pet− vs. CSF+/pet−; csf−/pet− vs. CSF+/PET+; csf−/PET+ vs. CSF+/pet−; csf−/PET+ vs. CSF+/PET+.
bcsf−/pet− vs. CSF+/PET+.
ccsf−/pet− vs. CSF+/pet−; csf−/pet− vs. CSF+/PET+; csf−/PET+ vs. CSF+/pet−; csf−/PET+ vs. CSF+/PET+; CSF+/pet− vs. CSF+/PET+.
dcsf−/pet− vs. csf−/PET+; csf−/pet− vs. CSF+/PET+; csf−/PET+ vs. CSF+/pet−; csf−/PET+ vs. CSF+/PET+; CSF+/pet− vs. CSF+/PET+.
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RAVLT-learning subscale, when compared to the
csf−/pet− group. Only the CSF+/PET+ group presented
with significant rates of cognitive decline compared to all
other groups (Supplementary Table 4). When examining the
severity of neuropsychiatric depressive symptoms,
we found that the GDS score was significantly higher in the
csf−/PET+ group (2.09 [2.07]), as compared to all
remaining groups (csf−/pet−: 1.48 [1.66]; CSF+/pet−:
1.50 [1.56]; CSF+/PET+: 1.44 [1.36]) (F(3,857)= 2.75,
p < 0.05) (Supplementary Table 4).
(iii) Genetic assessment revealed a significant association
between number of APOE-ε4 alleles and CSF/PET
amyloid-β biomarkers profile (χ2(6)= 197; p < 0.001;
Table 2). Although most of the association was driven by
fully negative vs. fully positive cases, csf−/PET+ cases
presented with a lower prevalence of APOE-ε4ε4 genotype
than expected (0%; standardized residual=−2). Isolated
PET positivity was associated with female sex (standardized
residual= 2.1; χ2(3)= 13.83; p < 0.005; Table 2).
(iv) When examining a series of confounding factors in
amyloid-β fluid and molecular imaging assessments
(Supplementary Table 5), we found no differences across
concordant and discordant CSF/PET groups, namely: (a)
size of ventricles, as a proxy for disrupted CSF clearance
mechanisms [52] was not disproportionally affected in
cases with discordant amyloid-β biomarkers compared to
CSF+/PET+ cases (csf−/PET+: 0.02 ± 0.02; CSF+/pet−:
0.03 ± 0.02; CSF+/PET+: 0.03 ± 0.01); (b) no significant
difference was reported for frequency/severity of sleep
disturbances, previously associated with CSF amyloid-β42
changes [53] (F(3,852)= 0.26, p= 0.854); (c) time interval
between [18F]Florbetapir injection and start of image
acquisition was not increased in cases with discordant
amyloid-β biomarkers (F(3,857)= 1.40, p= 0.242); (d)
occurrence of infarcts (χ2(3)= 2.69, p= 0.442) as
well as volume of white matter hyperintensities (F(3,808)=
0.57, p= 0.634) within the SUVr reference region did
not differ between groups. Finally, lack of
significantly decreased CSF amyloid-β40 levels in csf−/
PET+ individuals (csf−/pet−: 8718.85 pg/ml; csf−/PET+:
9788.26 pg/ml), together with presence of relevant,
but not severe, levels of occipital amyloid-β retention
Fig. 2 Trajectories of biomarker changes across cases with con-
cordant and discordant amyloid-β biomarkers. Alluvial plots
show trajectories of biomarker changes in csf−/pet−, csf−/PET+,
CSF+/pet− and CSF+/PET+ cases (from top left corner, clockwise).
Two time points are displayed for each group, i.e., baseline and 2-year
follow-up. bl baseline, 2y 2-year follow-up.
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(csf−/pet−: 0.75 [0.06]; csf−/PET+: 0.83 [0.06]; CSF+/
PET+: 0.94 [0.13]) makes it unlikely that csf−/PET+ cases
are due to cerebral amyloid angiopathy.
Discussion
Discordance in CSF and PET measures of amyloidosis is
fairly common, occurring in ≈20% of individuals at pre-
clinical and prodromal stages of Alzheimer’s disease [15].
Yet, guidelines on how to correctly interpret discordant
CSF/PET results are lacking. In this study, we validated
the hypothesis that discordance in CSF/PET amyloid-β
biomarkers provides unique information and that the
existence of discordant groups may result from differ-
ences in amyloid-β processing and kinetics in the CSF vs.
in the brain. Through systematic assessment of
discordant amyloid-β biomarker results at both cross-
sectional and longitudinal levels, we showed that bio-
marker discordance represents a natural phase in the
progression of amyloid-β pathology, with either CSF or
PET amyloid-β biomarkers becoming abnormal first and
not concurrently. We subsequently identified two
mutually exclusive trajectories (“CSF-first” vs. “PET-
first”) toward established amyloid-β pathology, char-
acterized by different genetic profiles and rates of
amyloid-β accumulation (“fast” vs. “slow” accumulators,
respectively). In addition, we showed that biomarker
discordance was not due to systematic errors in CSF and
PET measurements. Instead, biomarker discordance car-
ried prognostic relevance as a marker of progression
toward established amyloid-β pathology, thus allowing
identification of individuals at subsequent risk of clinical
progression, cognitive decline, increased neurodegenera-
tion, and tau pathology.
First, for the longitudinal cohort as a whole, decreased
CSF amyloid-β42 levels at baseline were predictive of
subsequent increases in amyloid-β plaques in the brain as
measured by longitudinal [18F]Florbetapir PET (Fig. 1).
This observation supports the concept that decreased CSF
amyloid-β42 might be a proxy for the rate at which
soluble amyloid-β isoforms are being trapped into non-
soluble amyloid-β aggregates in the brain as measured by
PET. Consistent with this observation, and in participants
with normal CSF/PET amyloid-β biomarkers, CSF
amyloid-β42, and [18F]Florbetapir PET levels did not
become pathological at the same time. Preferentially, CSF
amyloid-β42 became abnormal first without detectable brain
[18F]Florbetapir PET uptake (7% of csf−/pet− cases pro-
gressed to CSF+/pet−). This evidence, coupled with the
finding that about 30% of CSF+/pet− cases progressed to
CSF+/PET+, qualifies isolated CSF positivity as a pre-
ferential pathway from fully normal to fully pathological
amyloid-β biomarkers, consistent with previous
reports [19, 24].
However, our cross-sectional and longitudinal analyses
in this large cohort provided evidence for the existence of
an additional alternative pathway, where [18F]Florbetapir
PET became abnormal first. Firstly, and consistent with
previous reports [6–8, 13–15, 17, 18, 20–32, 34] (Supple-
mentary Table 1), we observed isolated [18F]Florbetapir
PET positivity in a non-negligible percentage of cases. This
cross-sectional evidence alone questions whether isolated
CSF amyloid-β42 positivity represents the only possible
pathway toward fully abnormal amyloid-β biomarkers.
Indeed, our longitudinal results showed that—in a propor-
tion of participants with normal amyloid-β biomarkers at
baseline—[18F]Florbetapir PET became abnormal first,
while levels of CSF amyloid-β42 were still normal (3.5% of
csf−/pet− cases progressed to csf−/PET+). In addition,
about 20% of the participants with isolated pathological
[18F]Florbetapir PET progressed to CSF+/PET+. These
longitudinal data suggest that cases with isolated [18F]
Florbetapir PET positivity are part of an alternative
Fig. 3 Trajectories toward full
amyloid-β biomarkers
abnormality. The figure shows
the different trajectories toward
full abnormality in amyloid-β
biomarkers. Different possible
pathways, i.e., either CSF
amyloid-β42 positivity first or
[18F]Florbetapir PET positivity
first, are possible.
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(PET-first) pathway toward established amyloid-β pathol-
ogy (Fig. 3).
Of note, the frequency of progression from csf−/pet− to
either CSF+/pet− or PET+/csf− was not significantly
different; this finding supports the concept that both CSF-
first and PET-first pathways are relevant. Furthermore, our
study found a slower rate of [18F]Florbetapir PET accu-
mulation in the csf−/PET+ compared to the CSF+/pet−
group. Thus, the existence of cases with discordant bio-
markers could be partly explained by differences in
amyloid-β accumulation dynamics, with csf−/PET+ and
CSF+/pet− cases representing “slow” and “fast” amyloid-β
accumulators, respectively. This explanation is also sup-
ported by the lower prevalence of APOE-ε4ε4 genotype
among csf−/PET+ individuals found in this study
(Table 2), considering that a slower rate of amyloid-β pla-
que accumulation is found in non-APOE-ε4 carriers com-
pared to APOE-ε4 carriers [54]. In contrast, CSF+/pet−
cases, despite presenting no evidence of significant
amyloid-β PET tracer retention, accumulated plaques in the
brain at a relatively fast rate, a finding consistent with the
higher prevalence of APOE-ε4ε4 genotype found in the
CSF+/pet− group compared to that in the csf−/PET+
group (Table 2).
On a technical note, it has been argued that occurrence of
discordant findings might be inherently dependent on the
choice of cutoffs to establish biomarkers’ abnormality [36].
Still, independently of the type of cutoffs adopted, previous
studies consistently reported a proportion of discordant
amyloid-β biomarker results, even when using cutoffs spe-
cifically designed to optimize agreement between bio-
markers [14, 16–18, 20, 21, 23, 25–27, 29–31]
(Supplementary Table 1). Similarly, it has been proposed
that discordant cases might be due to false negative or false
positive results, CSF analytical factors or failed PET scans
[19]. Our assessment of a comprehensive series of con-
founding factors in this study argues against this explana-
tion. Altogether, our results argue against the claim that
discordant findings in amyloid-β biomarkers systematically
represent false positive/negative results, suggesting instead
that amyloid-β biomarkers discordance, per se, carries
relevant information with respect to brain amyloid-β burden
and accumulation rate. Most importantly, amyloid-β bio-
markers discordance represents a strong predictor of future
progression toward full amyloid-β biomarkers abnormalities
(Fig. 2), thus allowing prompt identification of individuals
that will be at higher subsequent risk for clinical progression
and cognitive decline, steeper rates of neurodegeneration,
and tau pathology [14, 15, 19, 28].
This study has some limitations. We acknowledge that
the sample size of discordant biomarker groups was rela-
tively limited (n= 62 for CSF+/pet− and n= 44 for csf−/
PET+ cases). Although we used all longitudinal CSF/PET
data available from ADNI at the time of our study, joint
CSF/PET examinations were available at two longitudinal
time points only, thus future studies incorporating addi-
tional longitudinal CSF/PET time points will be valuable to
confirm our findings.
In conclusion, biomarker discordance allows for identi-
fication of individuals with elevated risk of progression
toward fully abnormal amyloid-β biomarkers, with sub-
sequent risk of neurodegeneration and cognitive decline.
Our results also suggest that there are two alternative
pathways (“CSF-first” vs. “PET-first”) toward established
amyloid-β pathology, characterized by different genetic
profiles and rates of amyloid-β accumulation. In conclusion,
CSF and PET amyloid-β biomarkers provide com-
plementary rather than redundant information, with poten-
tial implications for their use as biomarkers in clinical trials.
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